TG Therapeutics reported $0.35 in EPS Earnings Per Share for its fiscal quarter ending in September of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2026 0.35 0.40 2.43 Nov/09
FY2026Q2 Jun/2026 0.05 0.33 0.17 Aug/03
FY2026Q1 Mar/2026 0.12 0.28 0.03 May/06
FY2025Q4 Dec/2025 0.14 0.33 0.15 Feb/26
FY2025Q3 Sep/2025 2.43 0.25 0.02 Nov/03




Eps Change Date
AbbVie USD 3.82 0.17 Sep/2026
Alaunos Therapeutics USD -0.39 0.12 Jun/2026
Amgen USD 6.45 0.16 Sep/2026
Ardelyx USD -0.07 0.08 Jun/2026
Arrowhead Research USD -5.11 3.75 Sep/2026
Bayer EUR 0.31 0.64 Sep/2026
Biogen USD 2.62 0.98 Sep/2026
Corcept Therapeutics USD 1.01 0.65 Sep/2026
Curis USD -11.82 13.04 Mar/2026
Gilead Sciences USD 2.55 9.3 Sep/2026
J&J USD 2.7 0.2 Sep/2026
Karyopharm Therapeutics USD -1.02 1.2 Mar/2026
Novartis USD 2.46 0.05 Sep/2026
Novavax USD 0.13 0.59 Dec/2025
PTC Therapeutics USD -0.62 1.54 Sep/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 20.07 5.78 Sep/2026
Roche Holding CHF 10.98 2.61 Jun/2026
TG Therapeutics USD 0.35 0.3 Sep/2026
Verastem USD -0.44 0.04 Mar/2026
Vertex Pharmaceuticals USD 4.76 0.03 Sep/2026